As part of the collaboration, Biogen will leverage Envisagenics' proprietary artificial intelligence-driven RNA splicing platform, SpliceCore, to define and understand the regulation of different RNA isoforms in CNS cell types.

The collaboration aims to identify, test, and validate splicing errors at scale. Biogen will gain access to SpliceCore's database of approximately 7 million potential RNA splicing errors, providing Biogen with a broader lens to evaluate splicing events that may be targeted for therapeutic gain.

Financial details of the collaboration were not disclosed.

Biogen set to build new gene therapy manufacturing site
Biogen is planning to build a new manufacturing facility spanning 175,000 sq ft at its base in Research Triangle Park, NC, to support development of its...

ViGeneron, Biogen to develop AAV-based gene therapies for eye disease
ViGeneron and Biogen have signed a global collaboration and licensing agreement to develop and commercialize gene therapy products based on adeno-associated...

Ionis doses ALS patients with antisense medicine in clinical trial
Ionis Pharmaceuticals has dosed the first patients with ION541, an investigational antisense medicine developed to treat most forms of amyotrophic lateral...

Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.